Group 4 Created with Sketch.
Your changes have been saved

How a Long Effort to Protect Against RSV May Lead to a Better COVID-19 Vaccine

Share
station description The Big4Bio Podcast shares podcasts that give ins…
‎The Big4Bio Podcast
Duration: 23:57
Respiratory syncytial virus is the leading cause of infant hospitalization in the United States and a significant cause of morbidity and mortality in older adults. The virus causes more than 118,000 deaths per year and more than 3 million hospitalizations in children under the age of five. While man
Snippets are a new way to share audio!
You can clip a small part of any file to share, add to playlist, and transcribe automatically. Just click the to create your snippet!
Snippets: Clips of How a Long Effort to Protect Against RSV May Lead to a Better COVID-19 Vaccine that people like
There are currently no snippets from How a Long Effort to Protect Against RSV May Lead to a Better COVID-19 Vaccine.
Snippets are an easy way to highlight your favorite soundbite from any piece of audio and share with friends, or make a trailer for ‎The Big4Bio Podcast
Playlists that How a Long Effort to Protect Against RSV May Lead to a Better COVID-19 Vaccine appears on.
There are currently no playlists containing this audio.
Add this audio track to one of your playlists
Add to Playlist
Up Next
Full Description
Back to Top
Respiratory syncytial virus is the leading cause of infant hospitalization in the United States and a significant cause of morbidity and mortality in older adults. The virus causes more than 118,000 deaths per year and more than 3 million hospitalizations in children under the age of five. While many pharmaceutical companies have sought to develop a vaccine against RSV, it’s been an elusive target. Meissa Vaccines is developing a live attenuated RSV vaccine using its platform technology to replace viral genes that inhibit the immune response. The company is also advancing a vaccine for COVID-19 capitalizing on the same approach. We spoke to Marty Moore, founder and CEO of Meissa Vaccines, about its platform technology, how it works, and why its approach could provide significant benefits over existing COVID-19 vaccines.
Up Next
Add to playlist
New playlist

Embed

COPY
Embed Options
Create Playlist
Select the Station you want to upload this audio to
Station
0 / 140
0 / 2000
Playlist Icon Image:
(.jpg, .png, min size 500x500px)
Privacy
Subscribers
Your
voice
matters.
Discover & Listen to the world’s largest free collection of audio
Password reset

Enter your email address that you used to register. We'll send you an email with your username and a link to reset your password.



If you still need help, contact Vurbl Support
Password reset sent

You have been sent instructions on resetting you password to the email associated with your account. Please check your email and signing in again.


Back to Sign In
If you still need help, contact Vurbl Support
Your
voice
matters.
Discover & Listen to the world’s largest free collection of audio
Reset password

Please enter your new password below.



If you still need help, contact Vurbl Support
Your voice matters.
Discover & Listen to the world’s largest free collection of audio
Verify Email

Enter your email address that you used to register. We'll send you an email with a link to verify your email.



Cancel
Delete Profile
Are you sure? We will miss you :'(
Delete
Delete Audio
Are you sure?
Delete
Delete Playlist
Are you sure you want to delete this playlist?
Delete
Notifications Mark all as read
    You currently have no notifications
    Edit Snippet
    0 / 140
    0 / 140